Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Journal of Environmental Pathology, Toxicology and Oncology
IF: 1.625 5-Year IF: 1.63 SJR: 0.402 SNIP: 0.613 CiteScore™: 2.3

ISSN Print: 0731-8898
ISSN Online: 2162-6537

Journal of Environmental Pathology, Toxicology and Oncology

DOI: 10.1615/JEnvironPatholToxicolOncol.2016012256
pages 355-364

Inhibition of the p53 Y220C Mutant by 1-Hydroxy-2- Methylanthraquinone Derivatives: A Novel Strategy for Cancer Therapy

Vidhula Ahire
LARIA, iRCM, François Jacob Institute, DRF-CEA, Caen, France; UMR6252 CIMAP, CEA - CNRS– ENSICAEN, Université de Caen Normandie, Caen, France
D. Das
Department of Biotechnology, Siddhaganga Institute, Tumkur
Kaushala Prasad Mishra
Department of Life Sciences, University of Mumbai, Mumbai, India; Nehru Gram Bharati University, Allahabad, UP, India; Foundation for Education and Research, India and BM International Research Centre, Mumbai, India
G. R. Kulkarni
School of Basic Medical Science, University of Pune, Pune- 411007, India
L. Ackland
Centre for Cellular & Molecular Biology, School of Life and Environmental Sciences, Deakin University, Australia


Y220C, a substitution mutation in p53, causes major structural changes in the protein and is known to form a new protein cavity. This cavity is reckoned to accommodate small drug candidates that may play a key role in cancer treatment. Present study was aimed at determining a drug candidate that could inhibit the mutant p53 based on structural drug rationale. Docking of mutated p53 was performed to determine the drug of choice from the derivatives of 1-hydroxy-2- methylanthraquinone exhibiting anti-cancer properties. The cavity had been tested for identification of an accurate position vector for molecular docking studies using structure based drug design. The docked structure was validated using discovery studio 3.5. The best choice of two molecules were obtained by docking in specific solvent for 6 nanoseconds at a temperature of 310 K. Out of a library of compounds, acetamido-2-carboxy-4-dimethylamino-2- hydroxybenzophenone satisfied the ADMET and was found to be a potential target for mutant p53. This ligand binds at the active site of the protein. Results of present study offer a rationale of the lead ligands that can rescue oncogenic p53 by targeting the mutation site. Therefore, it is suggestive that small molecules may serve as an effective and novel anti-cancer drug.

Articles with similar content:

Epidemiological and Clinical Aspects of Nonsteroidal Anti-inflammatory Drugs and Cancer Risks
Journal of Environmental Pathology, Toxicology and Oncology, Vol.21, 2002, issue 2
Edgar M. Moran
The Identification of Key Gene Expression Signature in Prostate Cancer
Critical Reviews™ in Eukaryotic Gene Expression, Vol.30, 2020, issue 2
Keshan Wang , Qi Cao , Yu Huang , Hailong Ruan , Zhengshuai Song , Xiaoping Zhang , Ke Chen
Biopolymers as Transdermal Drug Delivery Systems in Dermatology Therapy
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.27, 2010, issue 2
M.A. Navya, K. H. Basavaraj, Siddaramaiah, George Johnsy, R. Rashmi
Molecular Basis of Bicalutamide Response Alteration of Androgen Receptor Caused by Single Nucleotide Polymorphisms: An In Silico Investigation
Critical Reviews™ in Eukaryotic Gene Expression, Vol.29, 2019, issue 2
Noushin Hadian, Hossein Sazegar, Mehdi Sadeghi, Mohamad Reza Ganjalikhany, Farzaneh Mohamadi Farsani
Dual Role of p21 in the Progression of Cancer and Its Treatment
Critical Reviews™ in Eukaryotic Gene Expression, Vol.26, 2016, issue 1
Amna Parveen, Whang Wan Kyunn, Muhammad Sajid Hamid Akash, Kanwal Rehman